155204-28-7

Basic information

• Product Name: WAY 100634
• Synonyms: WAY 100634;N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl) ethyl)pyridin-2-aMine;4-(2-Methoxyphenyl)-N-2-pyridinyl-1-piperazineethanaMine;N-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)pyridine-2-aMine
• CAS NO: 155204-28-7
• Molecular Formula: C₁₈H₂₄N₄O
• Molecular Weight: 312.40936
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 155204-28-7.mol

Chemical Properties

• Melting Point: 63-64 °C
• Boiling Point: 507.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.151±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane
• PKA: 7.39±0.10(Predicted)
• CAS DataBase Reference: WAY 100634(CAS DataBase Reference)
• NIST Chemistry Reference: WAY 100634(155204-28-7)
• EPA Substance Registry System: WAY 100634(155204-28-7)

Safety Data

• Hazardous Substances Data: 155204-28-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
WAY 100634 is used as a research chemical for the investigation of the serotonin 5-HT1A receptor's role in various physiological and pathological processes. Its high selectivity for the 5-HT1A receptor makes it a valuable tool in understanding the receptor's function and its potential as a therapeutic target.
Used in Neuropharmacology:
In the field of neuropharmacology, WAY 100634 is used as a selective antagonist to study the effects of serotonin on the central nervous system. This helps researchers to better understand the role of serotonin in mood regulation, anxiety, and other neurological disorders.
Used in Antidepressant Research:
WAY 100634 is used as a research compound in the development of novel antidepressant medications. By blocking the 5-HT1A receptor, it can help researchers identify new pathways and targets for the treatment of depression and other mood disorders.
Used in Drug Delivery Systems:
Similar to gallotannin, WAY 100634 can also be incorporated into drug delivery systems to improve its bioavailability and therapeutic outcomes. These systems can be tailored to specific applications, such as targeting specific cell types or tissues, to enhance the effectiveness of WAY 100634 in treating various conditions.

Upstream product

• 146714-63-8 4-(2-methoxyphenyl)-1-(2-pyridinylaminocarbonyl)methylpiperazine 
• 5221-37-4 2-chloro-N-pyridin-2-ylacetamide 
• 929039-11-2 chloro-acetic acid-[2]pyridylamide; hydrochloride 
• 21057-39-6 2-chloro-1-[4-(2-methoxyphenyl)-1-piperazinyl]ethan-1-one 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 1202-34-2 di(pyridin-2-yl)amine 
• 43091-72-1 1-(2-chloroethyl)-4-(2-methoxyphenyl)piperazine 
• 109-09-1 2-chloropyridine 
• 40255-48-9 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine 
• 946530-05-8 trans-N-2-{2-[4-(2-methoxy-phenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-carboxymethylcyclohexane) carboxamide 
• 943962-57-0 methyl 4-((2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)(pyridin-2-yl)carbamoyl)cyclohexanecarboxylate 
• 504-29-0 2-aminopyridine 

Downstream Products

• 155204-26-5 4-fluoro-N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-pyridin-2-ylbenzylamide 
• 155204-27-6 p-MPPN 
• 162760-96-5 WAY-100635 

Relevant articles and documents

Copper-Mediated Radiofluorination of Arylstannanes with [18F]KF

A copper-mediated nucleophilic radiofluorination of aryl- and vinylstannanes with [18F]KF is described. This method is fast, uses commercially available reagents, and is compatible with both electron-rich and electron-deficient arene substrates. This method has been applied to the manual synthesis of a variety of clinically relevant radiotracers including protected [18F]F-phenylalanine and [18F]F-DOPA. In addition, an automated synthesis of [18F]MPPF is demonstrated that delivers a clinically validated dose of 200 ± 20 mCi with a high specific activity of 2400 ± 900 Ci/mmol.

Structural Insights into 5-HT1A/D4 Selectivity of WAY-100635 Analogues: Molecular Modeling, Synthesis, and in Vitro Binding

The resurgence of interest in 5-HT1A receptors as a therapeutic target requires the existence of highly selective 5-HT1A ligands. To date, WAY-100635 has been the prototypical antagonist of these receptors. However, this compound als

NOVEL SYNTHESIS METHOD

The present invention relates to a method of making compounds having affinity for the 1 A subtype of the serotonin receptor, i.e. 5HT1A. The method of the present invention provides advantages over the known methods of synthesis. The compounds

5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING

The present invention provides a novel compound of formula (I) useful for in vivo imaging of 5-HT1 A receptors in a subject. Also provided by the present invention is a precursor compound useful in the preparation of the compound of the inventi

EFFICIENT SYNTHETIC METHOD OF 18F-MEFWAY PRECURSOR

The present invention relates a novel method for preparing an 18F-mefway precursor. The present invention provides an efficient synthetic method of an 18F-mefway precursor, which comprises an improved the acid chloride coupling react

Moderate chemical modifications of WAY-100635 improve the selectivity for 5-HT1A versus D4 receptors

The selectivity for 5-HT1A versus D4 receptors is significantly increased when the basic side chain of WAY-100635 is replaced by a 4-phenylpiperazine (3e) or a 4-phenyl-1,2,3,6-tetrahydropyridine moiety (3i). The 4-phenyl-1,2,3,6-tet

Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N -{2-[4-(2-methoxyphenyl)piperazin-1-yl] ethyl}- N -(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor

Here we describe the design, synthesis, and pharmacological profile of 5-HT1A receptor ligands related to 1 (WAY-100635). The cyclohexyl moiety in 1 and its O-desmethylated analogue 3 were replaced by the bridgehead iodinated bridge-fused rings: adamantyl, cubyl, bicyclo[2.2.2]octyl, or bicyclo[2.2.1]heptyl. All analogues displayed a (sub)nanomolar affinity for the 5-HT1A receptor in vitro. Compounds 6b and 7b appeared to be selective for this receptor over other relevant receptors and could easily be iodinated with radioactive iodine-123. In humane hepatocytes, [ 123I]6b showed a low propensity for amide hydrolysis and a stable carbon-iodine bond. The biodistribution of [123I]6b and [ 123I]7b in rats revealed that the carbon-iodine bond was also stable in vivo. Unfortunately, the brain uptake and the specificity for both radioligands were significantly lower than those of the parent molecule 1. In conclusion, the designed tracers are not suitable for SPECT imaging.

Screening of 5-HT1A receptor antagonists using molecularly imprinted polymers

Molecular imprinting produces network polymers with recognition sites for imprint molecules. The high binding affinity and selectivity in conjunction with the polymers' physical robustness positions molecular imprinted polymers (MIPs) as candidates for us

Tc-labeled arylpiperazine derivatives for imaging serotonin receptor

The present invention relates to Tc-labeled arylpiperazine derivatives for imaging serotonin receptor and, more particularly, to arylpiperazine derivatives coupled with MAMA-disulfide, N2S2 or dimethyl-N2S2 chel